A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276Phase 3Recruiting
- Lead sponsor
- Bristol-Myers Squibb (Industry)
- Enrollment
- 530 (estimated)
- Start date
- 25 Feb 2025
- Primary completion
- 17 Aug 2027 (estimated)
- Study completion
- 14 Jul 2031
- Last update posted
- 13 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- BMS-986489 (Atigotatug+Nivolumab) Biological
- Atezolizumab Biological
- Carboplatin Drug
- Etoposide Drug
Conditions and primary outcome
- Extensive-Stage Small Cell Lung Cancer
Primary outcome
Overall Survival (OS) (Up to 5 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06646276.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06646276 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.